Q1: Does that addressable market incorporate impact of generic...

  1. 4,360 Posts.
    lightbulb Created with Sketch. 476
    Q1: Does that addressable market incorporate impact of generic price erosion?.
    Q2: How many competitors are there?
    Q3: Pharma co's generally spend 7%-8% of annual revenues on R&D. Of course, that's expenditure today, for (uncertaint) revenue tomorrow. So how much could we expect the partner co to pay in royalties? Their gross-margins are about 40%-50%. Their SG&A is about 20%-27% of revenues. Thus 15% maybe? 20%? Honest question.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
1.9¢
Change
0.000(0.00%)
Mkt cap ! $7.747M
Open High Low Value Volume
1.9¢ 1.9¢ 1.9¢ $46 2.436K

Buyers (Bids)

No. Vol. Price($)
6 674564 1.9¢
 

Sellers (Offers)

Price($) Vol. No.
2.0¢ 10000 1
View Market Depth
Last trade - 15.36pm 19/06/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.